SCHEMBL14401249

SCHEMBL14401249

Fc1cccc(/C=C\c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 12/20 1.00
PTGS1 P23219 3/20 0.64
PTGS2 P35354 1/20 0.64
RELA Q04206 1/20 0.63
NQO2 P16083 1/20 0.62
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
PKM P14618 1/20 0.56
MAPK1 P28482 1/20 0.56
THPO P40225 1/20 0.56
NPC1 O15118 1/20 0.56
CHRM5 P08912 1/20 0.56
GRM5 P41594 1/20 0.56
RAB9A P51151 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
CYP19A1 P11511 1/20 0.56
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700305 1.00 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL700304 1.00 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL29446272 1.00 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL9849735 0.93 NFE2L2 (0.91) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL700536 0.93 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL31317689 0.93 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL700537 0.93 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL698584 0.88 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL698583 0.88 NFE2L2 (1.00) NFE2L2PTGS1PTGS2RELANQO2
SCHEMBL9849732 0.86 NFE2L2 (0.78) NFE2L2PTGS1PTGS2RELANQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980954-B2 Substituted cis- and trans-stilbenes as therapeutic agents STC.UNM (US) 2015-03-17 US disclosed
US-20070249647-A1 Substituted CIS- and trans-stilbenes as therapeutic agents REGENTS OF THE UNIVERSITY OF NEW MEXICO 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249647-A1 Substituted CIS- and trans-stilbenes as therapeutic agents TGFB1, VHL, TMSB10 NFE2L2 68/4885PTGS1 26/4885PTGS2 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.